PT2156840E - Utilização de furoato de mometasona para tratar doenças pulmonares e das vias respiratórias - Google Patents

Utilização de furoato de mometasona para tratar doenças pulmonares e das vias respiratórias Download PDF

Info

Publication number: PT2156840E
Authority: PT; Portugal
Prior art keywords: mometasone furoate; respiratory tract; pulmonary diseases; treat pulmonary; allergic
Prior art date: 1994-01-27

Application number

PT09007995T

Other languages

English (en)

Inventor

Imtiaz A Chaudry

Nagamani Nagabhushan

James E Patrick

Mitchell Cayen

Joel A Sequeira

Keith B Nolop

Francis M Cuss

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-27

Filing date

1995-01-26

Publication date

2011-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2156840(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-01-26 Application filed by Schering Corp filed Critical Schering Corp

2011-10-18 Publication of PT2156840E publication Critical patent/PT2156840E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT09007995T 1994-01-27 1995-01-26 Utilização de furoato de mometasona para tratar doenças pulmonares e das vias respiratórias PT2156840E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18837294A	1994-01-27	1994-01-27

Publications (1)

Publication Number	Publication Date
PT2156840E true PT2156840E (pt)	2011-10-18

Family

ID=22692858

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT01119613T PT1174138E (pt)	1994-01-27	1995-01-26	Utilização de furoato de mometasona para tratar doenças de pulmão e das vias respiratórias
PT09007995T PT2156840E (pt)	1994-01-27	1995-01-26	Utilização de furoato de mometasona para tratar doenças pulmonares e das vias respiratórias
PT95909242T PT740550E (pt)	1994-01-27	1995-01-26	Uso de furoato de mometasona para tratamento das vias respiratorias e doencas dos pulmoes

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT01119613T PT1174138E (pt)	1994-01-27	1995-01-26	Utilização de furoato de mometasona para tratar doenças de pulmão e das vias respiratórias

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT95909242T PT740550E (pt)	1994-01-27	1995-01-26	Uso de furoato de mometasona para tratamento das vias respiratorias e doencas dos pulmoes

Country Status (29)

Country	Link
EP (6)	EP1192946A1 (pt)
JP (6)	JP3480736B2 (pt)
KR (1)	KR100234864B1 (pt)
CN (4)	CN101156860A (pt)
AT (5)	ATE216243T1 (pt)
AU (1)	AU691880B2 (pt)
CA (1)	CA2182086C (pt)
CO (1)	CO4340692A1 (pt)
CY (2)	CY2617B2 (pt)
CZ (1)	CZ219196A3 (pt)
DE (1)	DE69526425T2 (pt)
DK (3)	DK1174138T3 (pt)
ES (3)	ES2368827T3 (pt)
FI (2)	FI122395B (pt)
HK (4)	HK1040911B (pt)
HU (1)	HU227837B1 (pt)
IL (1)	IL112459A (pt)
MX (1)	MX9602246A (pt)
MY (1)	MY114665A (pt)
NO (2)	NO314535B1 (pt)
NZ (1)	NZ279979A (pt)
PE (1)	PE44995A1 (pt)
PL (1)	PL315575A1 (pt)
PT (3)	PT1174138E (pt)
SG (1)	SG47387A1 (pt)
SK (1)	SK283338B6 (pt)
TW (1)	TW329387B (pt)
WO (1)	WO1995020393A1 (pt)
ZA (1)	ZA95637B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE44995A1 (es) *	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5962445A (en) *	1996-05-09	1999-10-05	Amrad Operations Pty Ltd.	Treatment of asthma and airway diseases
US6068832A (en) *	1996-08-29	2000-05-30	Schering Corporation	Chlorofluorocarbon-free mometasone furoate aerosol formulations
DK0927037T3 (da) *	1996-08-29	2001-09-24	Schering Corp	Aerosolformuleringer af mometason-furoat uden chlorfluorcarbonhydrider
US5968547A (en)	1997-02-24	1999-10-19	Euro-Celtique, S.A.	Method of providing sustained analgesia with buprenorphine
EP0969816B1 (en) *	1997-03-20	2004-12-15	Schering Corporation	Preparation of powder agglomerates
US6503537B2 (en)	1997-03-20	2003-01-07	Schering Corporation	Preparation of powder agglomerates
US6495167B2 (en)	1997-03-20	2002-12-17	Schering Corporation	Preparation of powder agglomerates
JP3676674B2 (ja) *	1997-10-09	2005-07-27	シェーリングコーポレイション	噴霧のためのモメタゾンフロエート懸濁液
MY133181A (en) *	1998-09-10	2007-10-31	Schering Corp	Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en)	1999-03-03	1999-04-28	Novartis Ag	Organic compounds
SE9900833D0 (sv) *	1999-03-09	1999-03-09	Astra Ab	Novel combination
AU7859800A (en) *	1999-10-08	2001-04-23	Schering Corporation	Topical nasal treatment
ECSP003747A (es) *	1999-11-02	2002-05-23	Smithkline Beecham Corp	Metodo y composiciones para el tratamiento de las enfermedades pulmonares
GB0015876D0 (en)	2000-06-28	2000-08-23	Novartis Ag	Organic compounds
EP1311294A2 (en) *	2000-08-04	2003-05-21	Longwood Pharmaceutical Research, Inc.	Formulations of mometasone and a bronchodilator for pulmonary administration
TWI290145B (en)	2000-12-22	2007-11-21	Nippon Shinyaku Co Ltd	Preventives/remedies for inflammatory airway diseases
GB0207906D0 (en)	2002-04-05	2002-05-15	3M Innovative Properties Co	Formoterol and mometasone aerosol formulations
MXPA06003376A (es) *	2003-09-26	2006-06-08	Schering Corp	Tratamiento de enfermedad pulmonar.
WO2005037245A2 (en) *	2003-10-21	2005-04-28	Direct-Haler A/S	A multiple route medication for the treatment of rhinitis and asthma
US20070053843A1 (en) *	2003-10-28	2007-03-08	Dawson Michelle L	Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
ATE461693T1 (de) *	2004-01-21	2010-04-15	Schering Corp	Verfahren zur behandlung von akuten rhinosinusitis
US7858650B2 (en)	2004-10-22	2010-12-28	Ono Pharmaceutical Co., Ltd.	Medicinal composition for inhalation
US8324192B2 (en)	2005-11-12	2012-12-04	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en)	2005-11-12	2013-07-30	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en)	2005-11-12	2014-03-25	The Regents Of The University Of California	Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20090131386A1 (en)	2007-11-13	2009-05-21	Meritage Pharma, Inc.	Compositions for the treatment of inflammation of the gastrointestinal tract
CA2704949A1 (en)	2007-11-13	2009-05-22	Meritage Pharma, Inc.	Gastrointestinal delivery systems
US9623000B2 (en)	2008-07-31	2017-04-18	Dekel Pharmaceuticals Ltd	Compositions and methods for treating inflammatory disorders
DK2328553T3 (da) *	2008-08-20	2020-08-24	Univ California	Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen
JP2012505236A (ja) *	2008-10-10	2012-03-01	シェーリングコーポレイション	コルチコステロイド組成物およびそれの治療方法
US9370483B2 (en)	2013-09-13	2016-06-21	Glenmark Specialty S.A.	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en)	2013-09-13	2018-04-10	Glenmark Specialty S.A.	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10016443B2 (en)	2013-10-04	2018-07-10	Glenmark Specialty S.A.	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en)	2013-10-04	2020-02-04	Glenmark Specialty S.A.	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en)	2013-10-04	2020-05-19	Glenmark Specialty S.A.	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2015009429A (es)	2013-10-04	2015-10-09	Glenmark Pharmaceuticals Ltd	Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10758550B2 (en)	2013-10-04	2020-09-01	Glenmark Specialty S.A.	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en)	2014-10-03	2023-06-20	Glenmark Specialty S.A.	Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107260665B (zh) *	2016-04-08	2021-03-30	天津金耀集团有限公司	一种吸入用糠酸莫米松混悬液组合物
BR112020016817A2 (pt)	2018-02-23	2020-12-15	Glenmark Specialty S.A.	Método para tratar sintomas associados à rinite alérgica, método para fornecer um início de ação mais rápido para alívio da rinite alérgica e método para tratar um sujeito humano pediátrico que sofre de rinite alérgica
US12303635B2 (en)	2018-04-16	2025-05-20	Glenmark Specialty S.A.	Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN113933415B (zh) *	2021-09-30	2023-03-24	北京阳光德美医药科技有限公司	一种hplc-ms/ms测定人血浆中糠酸酯浓度的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0057401B1 (en)	1981-02-02	1984-08-01	Schering Corporation	Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
KR890000664B1 (ko) *	1981-10-19	1989-03-22	바리 안소니 뉴우샘	미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4731447A (en)	1985-05-13	1988-03-15	Schering Corporation	Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4972830A (en)	1985-07-31	1990-11-27	Vortran Medical Technology, Inc.	Inhalation device and method
US4873335A (en)	1986-03-12	1989-10-10	Schering Corporation	3-phenethyl-2-benzene-amides or aza-derivatives thereof
US4910192A (en) *	1987-12-04	1990-03-20	Sri International	Topically active steroidal anti-inflammatory agents
CA2058764A1 (en) *	1989-04-28	1990-10-29	Peter D. Hodson	Dry powder inhalation device
EP0965335B1 (en) *	1990-03-23	2003-09-17	Minnesota Mining And Manufacturing Company	Metered-dose aerosol formulations
ES2065701T3 (es) *	1990-09-10	1995-02-16	Schering Corp	Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
EP0512090B2 (en) *	1990-10-16	2006-11-22	Sonoran Desert Chemicals LLC	Treatment of inflammation
JP2769925B2 (ja) *	1990-10-18	1998-06-25	ミネソタマイニングアンドマニュファクチャリングカンパニー	ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
GB9105705D0 (en) *	1991-03-18	1991-05-01	Sandoz Ltd	Improvements in or relating to organic compounds
HUT67449A (en) *	1991-06-10	1995-04-28	Schering Corp	Aerosol formulations containing 1,1,1,2,3,3,3-heptafluoropropane
CA2111003A1 (en)	1991-06-10	1992-12-23	Julianne Fassberg	Non-chlorofluorocarbon aerosol formulations
NZ243314A (en)	1991-06-26	1994-07-26	Schering Corp	Powder dispenser; single metered dose rotated to dispensing conduit
DE4140689B4 (de) *	1991-12-10	2007-11-22	Boehringer Ingelheim Kg	Inhalationspulver und Verfahren zu ihrer Herstellung
CA2421976C (en) *	1991-12-12	2004-04-20	Glaxo Group Limited	Medicaments
IL104068A (en) *	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ATE128350T1 (de) *	1991-12-12	1995-10-15	Glaxo Group Ltd	Pharmazeutische aerosolformulierung.
WO1993017663A1 (en) *	1992-03-10	1993-09-16	Fisons Plc	Pharmaceutical inhalation compositions
GB9207400D0 (en) *	1992-04-02	1992-05-13	Smithkline Beecham Plc	Novel use
PE44995A1 (es) *	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

1995
- 1995-01-24 PE PE1995260142A patent/PE44995A1/es not_active Application Discontinuation
- 1995-01-26 EP EP01119615A patent/EP1192946A1/en not_active Ceased
- 1995-01-26 PT PT01119613T patent/PT1174138E/pt unknown
- 1995-01-26 CN CNA2007101867131A patent/CN101156860A/zh active Pending
- 1995-01-26 CO CO95002738A patent/CO4340692A1/es unknown
- 1995-01-26 CA CA002182086A patent/CA2182086C/en not_active Expired - Lifetime
- 1995-01-26 NZ NZ279979A patent/NZ279979A/en not_active IP Right Cessation
- 1995-01-26 AT AT95909242T patent/ATE216243T1/de active
- 1995-01-26 ES ES01119613T patent/ES2368827T3/es not_active Expired - Lifetime
- 1995-01-26 JP JP52007495A patent/JP3480736B2/ja not_active Expired - Lifetime
- 1995-01-26 CN CNB2004100324736A patent/CN100441192C/zh not_active Expired - Lifetime
- 1995-01-26 DE DE69526425T patent/DE69526425T2/de not_active Expired - Lifetime
- 1995-01-26 ES ES09007995T patent/ES2369516T3/es not_active Expired - Lifetime
- 1995-01-26 AU AU17271/95A patent/AU691880B2/en not_active Expired
- 1995-01-26 AT AT02001144T patent/ATE531364T1/de active
- 1995-01-26 TW TW084100705A patent/TW329387B/zh not_active IP Right Cessation
- 1995-01-26 EP EP02001144A patent/EP1201242B1/en not_active Expired - Lifetime
- 1995-01-26 HU HU9602043A patent/HU227837B1/hu unknown
- 1995-01-26 SK SK822-96A patent/SK283338B6/sk not_active IP Right Cessation
- 1995-01-26 DK DK01119613.6T patent/DK1174138T3/da active
- 1995-01-26 PT PT09007995T patent/PT2156840E/pt unknown
- 1995-01-26 PT PT95909242T patent/PT740550E/pt unknown
- 1995-01-26 WO PCT/US1995/000550 patent/WO1995020393A1/en not_active Ceased
- 1995-01-26 DK DK09007995.5T patent/DK2156840T3/da active
- 1995-01-26 IL IL11245995A patent/IL112459A/xx not_active IP Right Cessation
- 1995-01-26 EP EP01119614A patent/EP1174139B1/en not_active Expired - Lifetime
- 1995-01-26 AT AT01119614T patent/ATE525075T1/de not_active IP Right Cessation
- 1995-01-26 EP EP01119613A patent/EP1174138B1/en not_active Expired - Lifetime
- 1995-01-26 AT AT01119613T patent/ATE518520T1/de active
- 1995-01-26 AT AT09007995T patent/ATE519489T1/de active
- 1995-01-26 ZA ZA95637A patent/ZA95637B/xx unknown
- 1995-01-26 PL PL95315575A patent/PL315575A1/xx unknown
- 1995-01-26 SG SG1996000423A patent/SG47387A1/en unknown
- 1995-01-26 KR KR1019960704076A patent/KR100234864B1/ko not_active Expired - Lifetime
- 1995-01-26 CN CNB951913603A patent/CN100358528C/zh not_active Expired - Lifetime
- 1995-01-26 EP EP95909242A patent/EP0740550B1/en not_active Expired - Lifetime
- 1995-01-26 CZ CZ962191A patent/CZ219196A3/cs unknown
- 1995-01-26 DK DK95909242T patent/DK0740550T3/da active
- 1995-01-26 MX MX9602246A patent/MX9602246A/es active IP Right Grant
- 1995-01-26 EP EP09007995A patent/EP2156840B1/en not_active Expired - Lifetime
- 1995-01-26 ES ES95909242T patent/ES2173947T3/es not_active Expired - Lifetime
- 1995-01-26 CN CNA2007101867146A patent/CN101164542A/zh active Pending
- 1995-01-27 MY MYPI95000213A patent/MY114665A/en unknown
1996
- 1996-07-12 FI FI962828A patent/FI122395B/fi not_active IP Right Cessation
- 1996-07-26 NO NO19963132A patent/NO314535B1/no not_active IP Right Cessation
1998
- 1998-11-30 JP JP10340817A patent/JPH11286447A/ja not_active Withdrawn
2002
- 2002-02-27 HK HK02101490.1A patent/HK1040911B/en not_active IP Right Cessation
- 2002-02-27 HK HK02101491.0A patent/HK1040912A1/en unknown
- 2002-04-08 HK HK02102575.7A patent/HK1040918A1/en unknown
- 2002-05-21 HK HK02103767.3A patent/HK1041829A1/en unknown
- 2002-10-17 NO NO20025002A patent/NO328698B1/no not_active IP Right Cessation
2003
- 2003-06-03 JP JP2003158657A patent/JP2003313128A/ja not_active Withdrawn
2007
- 2007-10-19 JP JP2007273211A patent/JP2008031184A/ja not_active Withdrawn
2008
- 2008-07-02 JP JP2008174020A patent/JP5247265B2/ja not_active Expired - Lifetime
2011
- 2011-07-08 FI FI20115742A patent/FI123580B/fi not_active IP Right Cessation
- 2011-10-27 CY CY1100007A patent/CY2617B2/xx unknown
- 2011-10-27 CY CY1100006A patent/CY2616B2/xx unknown
- 2011-11-09 JP JP2011245814A patent/JP2012036222A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2008031184A (ja)	2008-02-14
HK1040918A1 (en)	2002-06-28
SK82296A3 (en)	1997-03-05
CO4340692A1 (es)	1996-07-30
IL112459A0 (en)	1995-03-30
AU691880B2 (en)	1998-05-28
CN101156860A (zh)	2008-04-09
HK1040911A1 (en)	2002-06-28
EP1174138B1 (en)	2011-08-03
FI123580B (fi)	2013-07-31
PT740550E (pt)	2002-08-30
JPH11286447A (ja)	1999-10-19
SG47387A1 (en)	1998-04-17
NO963132L (no)	1996-09-26
TW329387B (en)	1998-04-11
EP1174138A3 (en)	2002-01-30
CN100441192C (zh)	2008-12-10
EP1201242B1 (en)	2011-11-02
PT1174138E (pt)	2011-10-03
JP5247265B2 (ja)	2013-07-24
CN101164542A (zh)	2008-04-23
SK283338B6 (sk)	2003-06-03
EP0740550A1 (en)	1996-11-06
FI122395B (fi)	2011-12-30
EP2156840A2 (en)	2010-02-24
DE69526425D1 (de)	2002-05-23
IL112459A (en)	1999-04-11
JP2003313128A (ja)	2003-11-06
DE69526425T2 (de)	2002-12-05
EP1174139A2 (en)	2002-01-23
WO1995020393A1 (en)	1995-08-03
HK1135331A1 (en)	2010-06-04
NO963132D0 (no)	1996-07-26
ATE216243T1 (de)	2002-05-15
NO20025002D0 (no)	2002-10-17
CA2182086C (en)	2000-04-11
MX9602246A (es)	1997-07-31
MY114665A (en)	2002-12-31
ATE525075T1 (de)	2011-10-15
FI962828L (fi)	1996-07-12
ATE518520T1 (de)	2011-08-15
CY2617B2 (en)	2012-05-23
ZA95637B (en)	1995-07-26
NO20025002L (no)	1996-09-26
EP1174139B1 (en)	2011-09-21
CA2182086A1 (en)	1995-08-03
NO314535B1 (no)	2003-04-07
EP1174139A3 (en)	2002-01-30
FI20115742L (fi)	2011-07-08
NZ279979A (en)	2001-03-30
JP2008285497A (ja)	2008-11-27
CN1139384A (zh)	1997-01-01
JPH09501700A (ja)	1997-02-18
EP1201242A3 (en)	2003-12-03
HK1040912A1 (en)	2002-06-28
JP3480736B2 (ja)	2003-12-22
FI962828A0 (fi)	1996-07-12
ES2369516T3 (es)	2011-12-01
DK0740550T3 (da)	2002-06-24
CN100358528C (zh)	2008-01-02
EP1174138A2 (en)	2002-01-23
ATE519489T1 (de)	2011-08-15
EP0740550B1 (en)	2002-04-17
ATE531364T1 (de)	2011-11-15
KR100234864B1 (ko)	1999-12-15
NO328698B1 (no)	2010-04-26
HU227837B1 (en)	2012-05-02
ES2368827T3 (es)	2011-11-22
HU9602043D0 (en)	1996-09-30
ES2173947T3 (es)	2002-11-01
EP1201242A2 (en)	2002-05-02
JP2012036222A (ja)	2012-02-23
CN1531967A (zh)	2004-09-29
AU1727195A (en)	1995-08-15
PL315575A1 (en)	1996-11-12
EP1192946A1 (en)	2002-04-03
HUT74884A (en)	1997-02-28
PE44995A1 (es)	1995-12-18
CZ219196A3 (en)	1996-12-11
EP2156840B1 (en)	2011-08-10
HK1040911B (en)	2011-11-18
DK2156840T3 (da)	2011-11-21
HK1041829A1 (en)	2002-07-26
CY2616B2 (en)	2012-05-23
DK1174138T3 (da)	2011-11-21
EP2156840A3 (en)	2010-05-19

Publication	Publication Date	Title
PT2156840E (pt)	2011-10-18	Utilização de furoato de mometasona para tratar doenças pulmonares e das vias respiratórias
Pryor et al.	2008	Physiotherapy techniques
CY1109030T1 (el)	2014-07-02	Συνθεση για εισπνοη
BRPI0404017A (pt)	2005-06-07	Aparelho de tratamento de respiração de oscilação em alta frequência contìnua
Malik et al.	2019	Effectiveness of deep breathing exercises and incentive spirometry on arterial blood gases in second degree inhalation burn patients
Kwiatkowska et al.	2021	POST COVID-19 PATIENTS'REHABILITATION-POTENTIAL OF USING HALOTHERAPY IN THE FORM OF GENERALLY ACCESSIBLE INHALATORIA WITH DRY SALT AEROSOL.
CN221579280U (zh)	2024-08-23	一种一体化吸氧雾化面罩
RU2211015C2 (ru)	2003-08-27	Способ галотерапии обструктивных заболеваний легких
Schmidt	2023	Don’t let asthma symptoms interfere with activities of daily living
Matheson	1995	Practical tips on postpolio syndrome
Heath et al.	1998	Information from your family doctor: Taking care of chronic bronchitis
Wynne et al.	1973	Ambulatory care and rehabilitation in copd
Parthasarathy	2006	Emma’s nose
Parthasarathy	2006	SLEEP MEDICINE PEARLS
Solly	1905	The treatment of tubercular laryngitis.
Nambu et al.	1998	EFFECTIVENESS OF EXTERNAL CHEST COMPRESSION ON INHALATION THERAPY IN ASYMPTOMATIC PERIODS FOR ASTHMATIC CHILDREN-PILOT STUDY
WO1992011025A3 (en)	1992-09-17	Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases